Bristol-Myers Squibb Co (BMY.N) said it would buy privately held drugmaker Flexus Biosciences Inc for up to $1.25 billion to add an emerging class of cancer-fighting drugs to its pipeline.
Walter Capital Partners takes significant stake in Quebec educational games maker Passe-Temps
6 November 2026 · 1 min read
Truelink Capital’s GES buys CSG Creative from National Trade Productions
6 November 2026 · 2 mins read
MPE Partners’ Intermatic adds outdoor lighting-control products maker Sun-Tech
6 November 2026 · 2 mins read
Velocity Capital Management backs founder Griffin Haddrill with stake in LV8, Mirage
6 November 2026 · 1 min read
Aterian’s Outlook Group completes acquisition of Graham-backed ABX’s Pewaukee packaging facility
6 November 2026 · 1 min read
FPE Capital’s NoBlue2 adds PeopleWalking’s Spanish NetSuite business in Europe push
6 November 2026 · 1 min read
PE targets identity security as AI transforms threats: 6 deals
6 November 2026 · 3 mins read
